Health (Drugs and Poisons) Regulation 1996

Drug Therapy Protocol – Pharmacist
Opioid Treatment Program

Monitored Medicines Unit
Queensland Department of Health
Locked Bag 21
Fortitude Valley BC QLD 4006
Telephone 13 7846
Email: MRQ@health.qld.gov.au

Disclaimer: Please note that any material printed is regarded as an uncontrolled copy. It is the responsibility of the person printing the document to refer frequently to https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/legislation-standards/acts-regulation for updates.
Health (Drugs and Poisons) Regulation 1996
Drug Therapy Protocol – Pharmacist
Opioid Treatment Program

I, Jeannette Rosita Young, pursuant to the Health (Drugs and Poisons) Regulation 1996, section 64(1)(f) certify this document as the Drug Therapy Protocol – Pharmacist Opioid Treatment Program.

Circumstances and conditions
1. A pharmacist may administer or supply a controlled drug listed in Appendix 1, column 1 only:
   1.1 to a drug dependent or class of drug dependent person identified by the Chief Executive or delegate as participating in the Queensland Opioid Treatment Program, on the oral, written or electronic instruction of a doctor or nurse practitioner who holds a written approval under section 122(5) or an oral approval under section 122(6) of the Health (Drugs and Poisons) Regulation 1996; and
   1.2 by a route of administration for the drug stated in Appendix 1, column 2; and
   1.3 subject to the conditions for the drug stated in Appendix 1, column 3 (if any); and
   1.4 in accordance with a Queensland Clinical Guideline developed and approved by the Executive Director, Mental Health Alcohol and Other Drugs Branch, Clinical Excellence Division, Queensland Department of Health that meets the requirements in Appendix 2 (the relevant protocol).
2. The relevant protocol must be available to the pharmacist at the time the pharmacist is acting under this Drug Therapy Protocol.
3. Before administering and/or supplying a controlled drug, the pharmacist must be familiar with the contra-indication(s) and known side effects of the drug, and advise the patient accordingly.
4. If Consumer Medicine Information is available for a particular drug, the pharmacist must, where reasonably practicable, offer the information to each person to whom the pharmacist administers or supplies the drug.

Certification

Certified at Brisbane on this 4th day of April 2019.

Dr Jeannette Young
Chief Health Officer
Department of Health

Notes:
(a) The pharmacist must be aware that practising within the Drug Therapy Protocol does not relieve that person of their legal responsibility or accountability for that person’s actions and may not provide immunity in case of negligence.
(b) All other provisions of the Health (Drugs and Poisons) Regulation 1996 such as the packaging and labelling requirements for dispensed medicines apply.
(c) The relevant Queensland Clinical Guideline for this Drug Therapy Protocol is the "Queensland Medication-Assisted Treatment of Opioid Dependence: Clinical Guidelines 2018"
### Appendix 1

**DRUG THERAPY PROTOCOL: Pharmacist**

**Opioid Treatment Program**

<table>
<thead>
<tr>
<th>SCHEDULED SUBSTANCE</th>
<th>APPROVED ROUTES OF ADMINISTRATION</th>
<th>RESTRICTIONS/CONDITIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone Syrup/liquid</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>Buprenorphine (Subutex)</td>
<td>Sublingual tablets</td>
<td>For use in Queensland Opioid Treatment Program</td>
</tr>
<tr>
<td>Buprenorphine-Naloxone (Suboxone)</td>
<td>Sublingual film</td>
<td></td>
</tr>
</tbody>
</table>
Appendix 2

Clinical Guidelines – Minimum Requirements

1. The pharmacist must have and use the Queensland Medication-Assisted Treatment of Opioid Dependence: Clinical Guidelines 2018 as the Queensland Clinical Guideline that supports and details the clinical use, administration or supply of the controlled drugs listed in Appendix 1 of this Drug Therapy Protocol.

2. The Clinical Guideline must be developed by an inter-disciplinary team appointed by the Department of Health. As a minimum, the team must consist of a medical practitioner, pharmacist and a consumer representative and may include other identified professional personnel as considered appropriate by the Queensland Department of Health.

3. Following a period of three years or sooner if considered necessary, the Clinical Guideline must be reviewed by an inter-disciplinary team.

Content of a Queensland Medication-Assisted Treatment of Opioid Dependence Clinical Guideline

The Clinical Guideline clearly identifies the following:

1. The procedures for clinical assessment, management and follow-up of patients, including the recommended drug therapy for the relevant clinical problem.

2. A clinical indication or time when medical referral/consultation must occur for that condition.

3. The name, form and strength of the controlled drug and the condition/situation for which it is intended.

4. The recommended dose protocol of the controlled drug.

5. The route of administration of the controlled drug.

6. The frequency of administration of the controlled drug.

7. Details of potential side effects and major interactions.

8. The requirement for documented consent of the person to be administered the controlled drug.

9. The type of equipment and management procedures required for management of an emergency associated with the use of the controlled drug.

Endorsement of and Renewal of the Queensland Medication-Assisted Treatment of Opioid Dependence Clinical Guideline

1. A new or reviewed Clinical Guideline must be endorsed by the Executive Director, Mental Health Alcohol and Other Drugs Branch, Clinical Excellence Division, Queensland Department of Health.

2. The Clinical Guideline shall be reviewed every three (3) years or sooner if necessary from the date of endorsement by the Executive Director, Mental Health Alcohol and Other Drugs Branch, Clinical Excellence Division, Queensland Department of Health.